“We have seen remarkable results from clinical trials using AAV vectors for AADC gene transfer,” says Shin-ichi Muramatsu, a pioneer of AAV vector research, and a professor in Jichi Medical ...

This in silico approach aims to increase the fitness of clinical adeno-associated virus (AAV) capsids to make gene therapies more economically viable for patients. Developing AAV capsids with ...

For central nervous system (CNS) applications, attempts are being made to deliver AAV gene therapy directly to the brain parenchyma or the cerebrospinal fluid (CSF) space by intra-cisterna magna ...

The college we are going to tell you about is Army Air Defence College (AADC). Those who study from here directly become officers in the army. Army Air Defence College (AADC) Army Air Defence ...

Adeno-associated virus (AAV) gene therapies hold great promise, but ensuring product quality is critical. One major challenge? The presence of empty capsids, which can reduce therapeutic effectiveness ...

Gene therapy represents one of the fastest growing biotherapeutics worldwide, with AAV at the forefront. This rapid growth is constantly challenging CMC approaches, from manufacturing through release ...

Coave's proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid, ...

Developing AAV capsids with improved yield, or fitness, is a key strategy for reducing manufacturing costs in order to make gene therapies more affordable. Christian Mueller and coauthors from ...